Multiple sclerosis natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 13: Line 13:
* medication complication: Insufficient blood supply to the bone can cause avascular osteonecrosis. After trauma corticosteroid treatment is the most common cause of AVN.<ref name="pmid9365096">{{cite journal |vauthors=Yamamoto T, Irisa T, Sugioka Y, Sueishi K |title=Effects of pulse methylprednisolone on bone and marrow tissues: corticosteroid-induced osteonecrosis in rabbits |journal=Arthritis Rheum. |volume=40 |issue=11 |pages=2055–64 |date=November 1997 |pmid=9365096 |doi=10.1002/1529-0131(199711)40:11&lt;2055::AID-ART19&gt;3.0.CO;2-E |url=}}</ref><ref name="pmid12430099">{{cite journal |vauthors=Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME |title=Pathogenesis and natural history of osteonecrosis |journal=Semin. Arthritis Rheum. |volume=32 |issue=2 |pages=94–124 |date=October 2002 |pmid=12430099 |doi= |url=}}</ref>
* medication complication: Insufficient blood supply to the bone can cause avascular osteonecrosis. After trauma corticosteroid treatment is the most common cause of AVN.<ref name="pmid9365096">{{cite journal |vauthors=Yamamoto T, Irisa T, Sugioka Y, Sueishi K |title=Effects of pulse methylprednisolone on bone and marrow tissues: corticosteroid-induced osteonecrosis in rabbits |journal=Arthritis Rheum. |volume=40 |issue=11 |pages=2055–64 |date=November 1997 |pmid=9365096 |doi=10.1002/1529-0131(199711)40:11&lt;2055::AID-ART19&gt;3.0.CO;2-E |url=}}</ref><ref name="pmid12430099">{{cite journal |vauthors=Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME |title=Pathogenesis and natural history of osteonecrosis |journal=Semin. Arthritis Rheum. |volume=32 |issue=2 |pages=94–124 |date=October 2002 |pmid=12430099 |doi= |url=}}</ref>


* Fatigue: [[Fatigue]] is seen in almost 80% of [[MS]] patient. They commonly feel exhausted and out of energy. We can see fatigue exacerbation before acute attacks in MS and for a while after that
* Fatigue: [[Fatigue]] is seen in almost 80% of [[MS]] patient. They commonly feel exhausted and out of energy. We can see fatigue exacerbation before acute attacks in MS and for a while after that.<ref name="pmid16900749">{{cite journal |vauthors=Krupp L |title=Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease |journal=Mult. Scler. |volume=12 |issue=4 |pages=367–8 |date=August 2006 |pmid=16900749 |doi=10.1191/135248506ms1373ed |url=}}</ref>


* mood problems: [[Psychiatric]] disorders especially [[depression]] is common and can be seen in almost 50% of [[MS]] patients. Some studies show higher risk of [[suicide]] in [[MS]] patient.
* mood problems: [[Psychiatric]] disorders especially [[depression]] is common and can be seen in almost 50% of [[MS]] patients.<ref name="pmid8618657">{{cite journal |vauthors=Sadovnick AD, Remick RA, Allen J, Swartz E, Yee IM, Eisen K, Farquhar R, Hashimoto SA, Hooge J, Kastrukoff LF, Morrison W, Nelson J, Oger J, Paty DW |title=Depression and multiple sclerosis |journal=Neurology |volume=46 |issue=3 |pages=628–32 |date=March 1996 |pmid=8618657 |doi= |url=}}</ref> Some studies show higher risk of [[suicide]] in [[MS]] patient.<ref name="pmid1866003">{{cite journal |vauthors=Sadovnick AD, Eisen K, Ebers GC, Paty DW |title=Cause of death in patients attending multiple sclerosis clinics |journal=Neurology |volume=41 |issue=8 |pages=1193–6 |date=August 1991 |pmid=1866003 |doi= |url=}}</ref><ref name="pmid1449409">{{cite journal |vauthors=Stenager EN, Stenager E |title=Suicide and patients with neurologic diseases. Methodologic problems |journal=Arch. Neurol. |volume=49 |issue=12 |pages=1296–303 |date=December 1992 |pmid=1449409 |doi= |url=}}</ref>


* Spasticity: Damage to the upper motor neurons and decrease inhibition of lower motor neurons in [[MS]] can increase muscle tone and rigidity in 75% of [[MS]] patients.
* Spasticity: Damage to the upper motor neurons and decrease inhibition of lower motor neurons in [[MS]] can increase muscle tone and rigidity in 75% of [[MS]] patients.<ref name="pmid17868019">{{cite journal |vauthors=Boissy AR, Cohen JA |title=Multiple sclerosis symptom management |journal=Expert Rev Neurother |volume=7 |issue=9 |pages=1213–22 |date=September 2007 |pmid=17868019 |doi=10.1586/14737175.7.9.1213 |url=}}</ref>


* Bowel and bladder dysfunction: [[Bowel]] and [[bladder]] dysfunction is common in [[MS]] patients and accurse in more than 50% of them. [[bladder]] dysfunction can be the result of [[Detrusor hyperactivity|Detrusor overactivity]], Detrusor sphincter dyssynergia, Inefficient [[bladder]] [[contractility]] and Abnormal [[sensation]] and [[bladder]] hypoactivity. the most common [[bowel]] problems include [[Constipation]], poor [[defecation]] and [[incontinence]].
* Bowel and bladder dysfunction: [[Bowel]] and [[bladder]] dysfunction is common in [[MS]] patients and accurse in more than 50% of them.<ref name="pmid12515563">{{cite journal |vauthors=DasGupta R, Fowler CJ |title=Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies |journal=Drugs |volume=63 |issue=2 |pages=153–66 |date=2003 |pmid=12515563 |doi= |url=}}</ref> [[bladder]] dysfunction can be the result of [[Detrusor hyperactivity|Detrusor overactivity]], Detrusor sphincter dyssynergia, Inefficient [[bladder]] [[contractility]] and Abnormal [[sensation]] and [[bladder]] hypoactivity.<ref name="pmid27116728">{{cite journal |vauthors=Wintner A, Kim MM, Bechis SK, Kreydin EI |title=Voiding Dysfunction in Multiple Sclerosis |journal=Semin Neurol |volume=36 |issue=2 |pages=219–20 |date=April 2016 |pmid=27116728 |doi=10.1055/s-0036-1582255 |url=}}</ref> the most common [[bowel]] problems include [[Constipation]], poor [[defecation]] and [[incontinence]].<ref name="pmid10631634">{{cite journal |vauthors=Hennessey A, Robertson NP, Swingler R, Compston DA |title=Urinary, faecal and sexual dysfunction in patients with multiple sclerosis |journal=J. Neurol. |volume=246 |issue=11 |pages=1027–32 |date=November 1999 |pmid=10631634 |doi= |url=}}</ref>


* Cognitive impairment: [[Cognitive disorder|Cognitive disorders]] is common in [[MS]] patients and can even present at early stages of disease. These disorders are in [[attention]], short term memory and information processing. Relapsing-remitting type of [[MS]] seems to have lower [[Cognitive disorder|cognitive problems]].
* Cognitive impairment: [[Cognitive disorder|Cognitive disorders]] is common in [[MS]] patients and can even present at early stages of disease. These disorders are in [[attention]], short term memory and information processing. Relapsing-remitting type of [[MS]] seems to have lower [[Cognitive disorder|cognitive problems]].

Revision as of 19:40, 1 March 2018

Multiple sclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple sclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Alternative Therapies

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple sclerosis natural history, complications and prognosis On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple sclerosis natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple sclerosis natural history, complications and prognosis

CDC on Multiple sclerosis natural history, complications and prognosis

Multiple sclerosis natural history, complications and prognosis in the news

Blogs on Multiple sclerosis natural history, complications and prognosis

Directions to Hospitals Treating Multiple sclerosis

Risk calculators and risk factors for Multiple sclerosis natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

Natural History

The symptoms of multiple sclerosis usually develop in the first/ second/ third decade of life, and start with symptoms such as optic neuritis, diplopia, sensory or motor loss, vertigo and balance problems. In young adult eye and sensory problems are prominent while in older patients we see motor problems more often.[1]

Complications

Complications that can develop as a result of mutiple sclerosis are:

  • medication complication: Insufficient blood supply to the bone can cause avascular osteonecrosis. After trauma corticosteroid treatment is the most common cause of AVN.[2][3]
  • Fatigue: Fatigue is seen in almost 80% of MS patient. They commonly feel exhausted and out of energy. We can see fatigue exacerbation before acute attacks in MS and for a while after that.[4]
  • Spasticity: Damage to the upper motor neurons and decrease inhibition of lower motor neurons in MS can increase muscle tone and rigidity in 75% of MS patients.[8]
  • Cognitive impairment: Cognitive disorders is common in MS patients and can even present at early stages of disease. These disorders are in attention, short term memory and information processing. Relapsing-remitting type of MS seems to have lower cognitive problems.
  • Heat sensitivity: Patients with MS disease are more sensitive to heat. A slight increase in body temperature of these patients will lead to worsening of their signs and symptoms.
  • vertigo: Benign positional paroxysmal vertigo is the most common cause of vertigo in MS patient. In the course of the disease about 30-50% of patients experience this symptom.

Prognosis

there are some factors associated with a particularly poor prognosis among patients with multiple sclerosis but We can’t surly say what is the prognosis of MS patients.[12]

Relapsing versus progressive disease

Progressive form of MS seems to have worse prognosis in comparison to relapsing remitting form of MS. Disabilities start sooner in progressive form[13][14][15] but some studies showed that age of onset is more important in MS disability than the form of the disease.[16][17]

Early symptoms

Some first manifestations of MS disease like bowel and bladder dysfunction, seems to have a worse prognosis.[18]. Another study demonstrated that having so many symptoms at the onset of the disease have a worse prognosis than being monosymptom.[19]

Demographics

Onset of MS in Black Americans is in later age and they are more susceptible of having multifocal signs and symptoms and involvement of optic nerve and spinal cord.[20]

Sex

Women seems to have younger age of onset and so better prognosis than men.[13]

Smoking

Transition of RRMS to SPMS can be accelerated with smoking.[21]

References

  1. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC (February 1989). "The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability". Brain. 112 ( Pt 1): 133–46. PMID 2917275.
  2. Yamamoto T, Irisa T, Sugioka Y, Sueishi K (November 1997). "Effects of pulse methylprednisolone on bone and marrow tissues: corticosteroid-induced osteonecrosis in rabbits". Arthritis Rheum. 40 (11): 2055–64. doi:10.1002/1529-0131(199711)40:11&lt;2055::AID-ART19&gt;3.0.CO;2-E. PMID 9365096.
  3. Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME (October 2002). "Pathogenesis and natural history of osteonecrosis". Semin. Arthritis Rheum. 32 (2): 94–124. PMID 12430099.
  4. Krupp L (August 2006). "Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease". Mult. Scler. 12 (4): 367–8. doi:10.1191/135248506ms1373ed. PMID 16900749.
  5. Sadovnick AD, Remick RA, Allen J, Swartz E, Yee IM, Eisen K, Farquhar R, Hashimoto SA, Hooge J, Kastrukoff LF, Morrison W, Nelson J, Oger J, Paty DW (March 1996). "Depression and multiple sclerosis". Neurology. 46 (3): 628–32. PMID 8618657.
  6. Sadovnick AD, Eisen K, Ebers GC, Paty DW (August 1991). "Cause of death in patients attending multiple sclerosis clinics". Neurology. 41 (8): 1193–6. PMID 1866003.
  7. Stenager EN, Stenager E (December 1992). "Suicide and patients with neurologic diseases. Methodologic problems". Arch. Neurol. 49 (12): 1296–303. PMID 1449409.
  8. Boissy AR, Cohen JA (September 2007). "Multiple sclerosis symptom management". Expert Rev Neurother. 7 (9): 1213–22. doi:10.1586/14737175.7.9.1213. PMID 17868019.
  9. DasGupta R, Fowler CJ (2003). "Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies". Drugs. 63 (2): 153–66. PMID 12515563.
  10. Wintner A, Kim MM, Bechis SK, Kreydin EI (April 2016). "Voiding Dysfunction in Multiple Sclerosis". Semin Neurol. 36 (2): 219–20. doi:10.1055/s-0036-1582255. PMID 27116728.
  11. Hennessey A, Robertson NP, Swingler R, Compston DA (November 1999). "Urinary, faecal and sexual dysfunction in patients with multiple sclerosis". J. Neurol. 246 (11): 1027–32. PMID 10631634.
  12. Swanton J, Fernando K, Miller D (2014). "Early prognosis of multiple sclerosis". Handb Clin Neurol. 122: 371–91. doi:10.1016/B978-0-444-52001-2.00015-7. PMID 24507526.
  13. 13.0 13.1 Weinshenker BG (1994). "Natural history of multiple sclerosis". Ann. Neurol. 36 Suppl: S6–11. PMID 8017890.
  14. Confavreux C, Vukusic S, Moreau T, Adeleine P (November 2000). "Relapses and progression of disability in multiple sclerosis". N. Engl. J. Med. 343 (20): 1430–8. doi:10.1056/NEJM200011163432001. PMID 11078767.
  15. Tremlett H, Paty D, Devonshire V (January 2006). "Disability progression in multiple sclerosis is slower than previously reported". Neurology. 66 (2): 172–7. doi:10.1212/01.wnl.0000194259.90286.fe. PMID 16434648.
  16. Confavreux C, Vukusic S (March 2006). "Age at disability milestones in multiple sclerosis". Brain. 129 (Pt 3): 595–605. doi:10.1093/brain/awh714. PMID 16415309.
  17. Confavreux C, Vukusic S (March 2006). "Natural history of multiple sclerosis: a unifying concept". Brain. 129 (Pt 3): 606–16. doi:10.1093/brain/awl007. PMID 16415308.
  18. Langer-Gould A, Popat RA, Huang SM, Cobb K, Fontoura P, Gould MK, Nelson LM (December 2006). "Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review". Arch. Neurol. 63 (12): 1686–91. doi:10.1001/archneur.63.12.1686. PMID 17172607.
  19. Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC (March 2006). "The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease". Brain. 129 (Pt 3): 584–94. doi:10.1093/brain/awh721. PMID 16401620.
  20. Cree BA, Khan O, Bourdette D, Goodin DS, Cohen JA, Marrie RA, Glidden D, Weinstock-Guttman B, Reich D, Patterson N, Haines JL, Pericak-Vance M, DeLoa C, Oksenberg JR, Hauser SL (December 2004). "Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis". Neurology. 63 (11): 2039–45. PMID 15596747.
  21. Roudbari SA, Ansar MM, Yousefzad A (July 2013). "Smoking as a risk factor for development of Secondary Progressive Multiple Sclerosis: A study in IRAN, Guilan". J. Neurol. Sci. 330 (1–2): 52–5. doi:10.1016/j.jns.2013.04.003. PMID 23628463.

Template:WH Template:WS